| Literature DB >> 26517867 |
Nathalie M M Benda1, Joost P H Seeger2, Guus G C F Stevens1, Bregina T P Hijmans-Kersten1, Arie P J van Dijk3, Louise Bellersen3, Evert J P Lamfers4, Maria T E Hopman1, Dick H J Thijssen2.
Abstract
INTRODUCTION: Physical fitness is an important prognostic factor in heart failure (HF). To improve fitness, different types of exercise have been explored, with recent focus on high-intensity interval training (HIT). We comprehensively compared effects of HIT versus continuous training (CT) in HF patients NYHA II-III on physical fitness, cardiovascular function and structure, and quality of life, and hypothesize that HIT leads to superior improvements compared to CT.Entities:
Mesh:
Year: 2015 PMID: 26517867 PMCID: PMC4627811 DOI: 10.1371/journal.pone.0141256
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow-chart of the inclusion of subjects.
Subject characteristics and cardiovascular medication.
| CT (n = 10) | HIT (n = 10) | Control (n = 9) | ||
|---|---|---|---|---|
| Age (yrs) | 64±8 | 63±8 | 67±7 | 0.57 |
| Sex (male:female) | 10:0 | 9:1 | 5:4 | 0.028 |
| Body weight (kg) | 89.7±11.9 | 87.6±23.6 | 77.0±10.5 | 0.16 |
| Height (cm) | 177±5 | 177±3 | 174±9 | 0.66 |
| Body mass index (kg/m2) | 28.9±4.7 | 28.1±7.5 | 25.4±2.7 | 0.24 |
| NYHA class (II:III) | 8:2 | 8:2 | 8:1 | 0.84 |
| Etiology (Isch:Non-isch) | 8:2 | 7:3 | 5:4 | 0.51 |
| Systolic blood pressure (mmHg) | 132±23 | 132±18 | 130±25 | 0.98 |
| Diastolic blood pressure (mmHg) | 83±11 | 79±10 | 78±14 | 0.48 |
| Resting heart rate (/min) | 59±11 | 57±7 | 60±10 | 0.80 |
| Maximal heart rate (/min) | 129±19 | 126±16 | 120±15 | 0.53 |
| Chronotropic incompetence (yes:no) | 5:4 | 8:2 | 6:1 | 0.33 |
| VO2peak
| 21.0±3.4 | 19.1±4.1 | 17.4±5.8 | 0.26 |
| VO2peak
| 86±8 | 79±17 | 81±22 | 0.63 |
| LVEF (%) | 38±6 | 37±6 | 40±11 | 0.84 |
| Medication | ||||
| Angiotensin converting enzyme-inhibitors | 5 (50%) | 6 (60%) | 8 (89%) | 0.19 |
| Angiotensin II receptor antagonists | 4 (40%) | 4 (40%) | 1 (11%) | 0.30 |
| Aldosterone antagonist | 6 (60%) | 7 (70%) | 8 (89%) | 0.36 |
| Diuretics (loopdiuretics) | 7 (70%) | 6 (60%) | 4 (44%) | 0.50 |
| β-blockers | 10 (100%) | 9 (90%) | 9 (100%) | 0.37 |
| Antiplatelet drugs | 6 (60%) | 4 (40%) | 3 (33%) | 0.47 |
| Coumarin derivates | 4 (40%) | 7 (70%) | 4 (44%) | 0.35 |
| Statins | 10 (100%) | 9 (90%) | 4 (44%) | 0.007 |
Data is presented as mean±SD. P-values refer to a 1-way ANOVA.
† Data was unavailable for 1 subject in the CT-group and 3 subjects in the control-group.
* Significantly less females compared to the control-group.
§Lower compared to CT-group and HIT-group.
Maximal incremental cycling test.
| CT (n = 10) | HIT (n = 10) | P-value | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| ||
| VO2peak (mL/min) | 1881±214 | 1887±27 | 1662±562 | 1792±559 | 0.06 | 0.44 | 0.08 | |
| VO2peak (mL/min/kg) | 21.2±3.6 | 21.3±3.7 | 19.1±4.1 | 20.4±4.3 | 0.10 | 0.14 | 0.09 | |
| VO2peak (% pred. VO2peak) | 86±8 | 87±10 | 79±17 | 85±16 | 0.044 | 0.48 | 0.08 | |
| Max. workload (Watt) | 145±22 | 152±26 | 126±38 | 142±45 | <0.001 | 0.24 | 0.07 | |
| Max. heart rate (/min) | 129±19 | 132±24 | 126±16 | 125±15 | 0.78 | 0.30 | 0.51 | |
| VE/VCO2 slope | 32.2±3.3 | 32.7±5.8 | 28.7±5.8 | 29.4±7.7 | 0.52 | 0.18 | 0.91 | |
| VO2 at AT (mL) | 1030±287 | 1248±388 | 1033±319 | 1090±225 | 0.041 | 0.54 | 0.22 | |
| Max. O2/HR (mL) | 16.2±2.2 | 16.7±2.8 | 14.0±4.0 | 15.4±3.8 | 0.006 | 0.25 | 0.13 | |
Data is presented as mean±SD. P-values refer to a 2-way repeated measures ANOVA between the two training groups. One subject in the CT-group did not reach VO2peak, and therefore only VE/VCO2 slope and VO2 at AT could be determined.
# For statistical reasons, data was analyzed with three separate tests to determine time, group and time*group P-values.
Brachial (BA) and superficial femoral artery (SFA) endothelium-dependent vasodilation through flow-mediated dilation (FMD), peak diameter and endothelium-independent dilation (GTN), and common carotid artery (CCA) intima-media thickness (IMT).
| CT (n = 10) | HIT (n = 10) | P-value | |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| BA diameter (mm) | 4.5±0.5 | 4.5±0.5 | 4.4±0.9 | 4.4±0.8 | 0.83 | 0.68 | 0.86 |
| BA FMD (%) | 5.2±2.5 | 4.8±3.0 | 5.3±2.6 | 4.7±2.5 | 0.33 | 0.92 | 0.98 |
| BA FMD (%, scaled) | 5.3±2.5 | 4.8±2.5 | 5.2±2.5 | 4.6±2.5 | 0.47 | >0.999 | 0.91 |
| BA SRAUC (s, 103) | 19.9±9.6 | 18.6±7.4 | 17.8±9.2 | 22.3±7.7 | 0.42 | 0.80 | 0.14 |
| BA GTN (%) | 17.6±7.0 | 16.3±6.5 | 16.8±8.7 | 15.2±4.9 | 0.33 | 0.74 | 0.92 |
| BA GTN (%, scaled) | 17.9±4.5 | 16.6±4.5 | 16.1±4.5 | 14.6±4.5 | 0.42 | 0.27 | 0.94 |
| BA FMD-GTN ratio | 0.34±0.21 | 0.33±0.24 | 0.42±0.30 | 0.34±0.15 | 0.46 | 0.63 | 0.82 |
| BA CADC (%) | 10.6±6.4 | 11.3±4.8 | 16.1±7.4 | 13.4±5.5 | 0.52 | 0.12 | 0.26 |
| BA CADC (%, scaled) | 11.0±4.2 | 12.0±4.2 | 15.0±4.2 | 12.8±4.2 | 0.72 | 0.11 | 0.27 |
| BA peak blood flow (mL/min) | 794±139 | 862±261 | 711±264 | 556±165 | 0.38 | 0.56 | 0.46 |
| SFA diameter (mm) | 7.1±1.2 | 6.9±1.2 | 6.7±1.1 | 6.5±1.0 | 0.38 | 0.48 | 0.88 |
| SFA FMD (%) | 3.3±1.9 | 5.1±4.8 | 4.2±1.8 | 3.4±2.8 | 0.58 | 0.74 | 0.19 |
| SFA FMD (%, scaled) | 3.5±2.9 | 5.1±2.9 | 4.1±2.9 | 3.1±2.9 | 0.74 | 0.50 | 0.19 |
| SFA SRAUC (s, 103) | 9.2±5.6 | 10.4±10.8 | 13.5±7.2 | 6.9±3.9 | 0.11 | 0.80 | 0.07 |
| CA IMT (mm) | 0.80±0.13 | 0.76±0.20 | 0.72±0.12 | 0.67±0.16 | 0.20 | 0.24 | 0.96 |
| CA IMT-to-lumen ratio | 0.12±0.02 | 0.11±0.02 | 0.11±0.02 | 0.11±0.02 | 0.40 | 0.59 | 0.45 |
Data is presented as mean±SD. P-values refer to 2-way repeated measures ANOVA between the 2 training groups.
# For statistical reasons, data was analyzed with three separate tests to determine time, group and time*group P-values. Due to technical problems, BA GTN/FMD-GTN ratio/peak blood flow was available for 9 subjects in the HIT-group and SFA FMD was available for 8 subjects in the HIT-group. CCA IMT and IMT-to-lumen ratio were available for 8 subjects in each group. SRAUC; shear rate area-under-the-curve. CADC; conduit artery dilating capacity.
Echocardiographic left ventricular volumes, systolic function, strain and diastolic function.
| CT (n = 10) | HIT (n = 10) | P-value | |||||
|---|---|---|---|---|---|---|---|
| Systolic function |
|
|
|
|
|
|
|
| LVEDV (ml) | 154±24 | 159±28 | 194±39 | 204±44 | 0.26 | 0.002 | 0.64 |
| LVESV (ml) | 98±14 | 102±19 | 134±32 | 132±40 | 0.87 | 0.037 | 0.63 |
| Stroke volume (ml) | 56±13 | 57±13 | 61±14 | 72±16 | 0.06 | 0.16 | 0.12 |
| LVEF (%) | 36±4 | 36±5 | 32±7 | 36±9 | 0.09 | 0.57 | 0.07 |
| Cardiac output (L/min) | 3.5±0.6 | 3.4±0.7 | 3.5±0.8 | 4.3±1.0 | 0.20 | 0.21 | 0.07 |
| Cardiac index (L/min/m2) | 1.7±0.3 | 1.6±0.3 | 1.7±0.4 | 2.1±0.5 | 0.22 | 0.14 | 0.08 |
| Longitudinal strain (%) | -9±3 | -9±3 | -9±3 | -8±3 | 0.60 | 0.47 | 0.38 |
| Circumferential strain (%) | -10±2 | -10±3 | -9±3 | -8±3 | 0.22 | 0.43 | 0.19 |
| Radial strain (%) | 23±7 | 22±6 | 23±8 | 20±8 | 0.13 | 0.71 | 0.48 |
| Area strain (%) | -17±4 | -15±6 | -17±5 | -14±5 | 0.044 | 0.73 | 0.97 |
| IVCT-L (ms) | 52±7 | 50±10 | 49±12 | 58±7 | 0.18 | 0.56 | 0.029 |
| IVCT-S (ms) | 57±14 | 59±11 | 53±9 | 56±11 | 0.35 | 0.46 | 0.87 |
|
| |||||||
| IVRT-L (ms) | 145±32 | 149±27 | 142±27 | 159±27 | 0.13 | 0.75 | 0.38 |
| IVRT-S (ms) | 160±36 | 148±22 | 164±41 | 170±37 | 0.60 | 0.45 | 0.22 |
| E/A | 1.15±0.71 | 1.17±0.89 | 1.53±1.42 | 1.60±1.53 | 0.49 | 0.36 | 0.59 |
| S/D | 1.38±0.74 | 1.17±0.34 | 1.00±0.40 | 1.26±0.59 | 0.85 | 0.48 | 0.14 |
| E/E’-L | 6.8±1.9 | 6.7±1.9 | 10.3±4.4 | 9.8±6.3 | 0.71 | 0.07 | 0.74 |
| E/E’-S | 10.1±4.1 | 11.1±5.2 | 12.6±9.8 | 11.8±11.2 | 0.93 | 0.67 | 0.42 |
Data is presented as mean±SD. P-values refers to 2-way repeated measures ANOVA between the 2 training groups.
# For statistical reasons, data was analyzed with three separate tests were performed to determine time, group and time*group P-values. 4D data was available for 7 patients in the CT-group and 8 patients in the HIT-group. IVCT-l, IVRT-C, IVRT-S and E/E’-L was available for 9 patients in the HIT-group. IVCT-S and E/E’-S was available for 8 patients in the HIT-group. IVCT-L and S/D ratio was available for 9 subjects in the CT-group. IVRT-L and E/A ratio was available for 8 subjects in the CT-group.
LVEDV; left ventricular end-diastolic volume. LVESV; left-ventricular end-systolic volume. IVCT-L/S: isovolumetric contraction time, lateral/septal. IVRT-L/S; isovolumetric relaxation time, lateral/septal. E/A ratio; peak mitral flow velocity during early filling/peak mitral flow velocity during atrial contraction. S/D; systolic flow velocity pulmonary vein/diastolic flow velocity pulmonary vein. E/E’-L/S; peak mitral flow velocity during early filling/peak mitral annulus velocity during early filling, lateral/septal.
Results of the SF-36 and Minnesota living with HF questionnaire (MLHFQ).
| CT (n = 9) | HIT (n = 8) | P-value | |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| Physical functioning | 74±22 | 78±17 | 57±21 | 69±17 | 0.004 | 0.16 | 0.11 |
| Physical health subscore | 73±20 | 76±16 | 60±22 | 67±19 | 0.15 | 0.26 | 0.52 |
| Mental health subscore | 81±9 | 83±10 | 83±5 | 82±10 | 0.75 | 0.87 | 0.54 |
| Total score | 75±16 | 78±13 | 68±14 | 73±14 | 0.18 | 0.42 | 0.76 |
|
|
|
| |||||
|
|
|
|
|
|
|
|
|
| Total score | 18±14 | 16±16 | 21±15 | 20±14 | 0.81 | 0.56 | 0.89 |
Data is presented as mean±SD. P-values refers to 2-way repeated measures ANOVA between the 2 training groups. Results of the SF-36 were scored on a 0–100 scale, in which a high score represents a better quality of life. Results of the MLHFQ were scored on a 0–105 scale, in which a low score indicates few HF-related complaints.
† Data was available for 7 subjects in the HIT-group.
‡ Data was available for 8 subjects in the CT-group.